PRCT · XBRL financial data

PROCEPT BioRobotics financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PRCT's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	34,473	75,014	136,191	224,498	308,054
Cost of revenue	18,608	37,929	65,142	87,399	111,828
Gross profit	15,865	37,085	71,049	137,099	196,226
Research and development	18,993	28,981	48,446	62,298	71,277
Selling, general and administrative	51,036	88,828	131,773	171,415	228,808
Total operating expenses	70,029	117,809	180,219	233,713	300,085
Operating income (loss)	(54,164)	(80,724)	(109,170)	(96,614)	(103,859)
Interest income	76	2,497	7,551	10,895	12,219
Interest expense	5,810	5,183	3,995	4,184	3,586
Other income (expense)	(154)	(203)	(176)	(1,396)	(156)
Income tax expense (benefit)	0	0	0	0	190
Net income (loss)	(59,853)	(87,154)	(105,897)	(91,413)	(95,572)
Earnings per share, basic USD per share	(3.63)	(1.96)	(2.24)	(1.75)	(1.72)
Earnings per share, diluted USD per share	(3.63)	(1.96)	(2.24)	(1.75)	(1.72)
Weighted average shares, basic thousands of shares	16,480	44,400	47,255	52,125	55,544
Weighted average shares, diluted thousands of shares	16,480	44,400	47,255	52,125	55,544

Fiscal years (PRCT's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	304,320	221,859	257,222	333,725	286,503
Accounts receivable	4,464	15,272	48,376	83,496	83,533
Inventory	13,147	28,543	39,756	56,168	70,694
Prepaid and other current assets	4,242	6,175	5,213	8,453	9,648
Total current assets	326,173	272,626	350,567	481,842	450,378
Property and equipment, net	5,045	8,656	28,748	26,709	30,399
Right-of-use asset	3,279	23,481	20,241	18,941	17,538
Total assets	337,024	309,329	404,717	534,017	508,081
Accounts payable	2,029	9,391	13,499	10,032	17,285
Current portion of long-term debt	0	—	—	—	—
Total current liabilities	16,242	35,290	45,927	53,133	65,795
Long-term debt	50,004	51,213	51,339	51,472	51,615
Lease liability, non-current	1,991	23,975	26,182	26,868	24,654
Total liabilities	69,933	112,257	123,965	131,797	142,211
Accumulated deficit	(261,521)	(348,675)	(454,572)	(545,985)	(641,557)
Total stockholders' equity	267,091	197,072	280,752	402,220	365,870
Total liabilities and equity	337,024	309,329	404,717	534,017	508,081
Common shares outstanding (cover page) thousands of shares	43,989	44,866	50,964	54,819	56,390

Fiscal years (PRCT's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(59,853)	(87,154)	(105,897)	(91,413)	(95,572)
Stock-based compensation	3,796	10,337	19,134	31,840	47,603
Depreciation and amortization	3,324	2,841	3,807	5,234	6,390
Net cash from operating activities	(57,334)	(80,382)	(108,003)	(99,213)	(48,985)
Purchases of property and equipment	592	2,653	25,206	4,409	9,356
Net cash from investing activities	(592)	(2,653)	(25,206)	(4,409)	(9,356)
Proceeds from issuing common stock	0	2,409	161,705	164,523	0
Repayments of long-term debt	0	50,000	0	0	—
Net cash from financing activities	262,116	3,612	167,795	180,125	11,193
Net change in cash	204,190	(79,423)	34,586	76,503	(47,222)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
PROCEPT BioRobotics	227,914	94,498	(19,251)*	57.3M	11.8 quarters	Q2 FY26 10-QJun 30, 2026
Icu Medical	298,299	551,683	80,150*	25.0M	—	Q2 FY26 10-QJun 30, 2026
Dentsply Sirona	239,000	898,000	99,000*	199.4M	—	Q2 FY26 10-QJun 30, 2026
Inspire Medical Systems	190,803	206,695	46,426*	29.0M	—	Q3 FY26 10-QSep 30, 2026
Masimo	124,600	403,600	45,300	52.4M	—	Q1 FY26 10-QApr 4, 2026
LivaNova	516,619	390,587	66,588*	55.1M	—	Q2 FY26 10-QJun 30, 2026
Envista Holdings	1,125,600	730,500	119,200*	160.6M	—	Q2 FY26 10-QJul 3, 2026
Integer Holdings	14,135	449,661	36,631*	34.0M	—	Q3 FY26 10-QOct 2, 2026
TransMedics Group	491,113	189,948	17,309*	34.7M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.